Forte Biosciences (NASDAQ:FBRX) Price Target Raised to $64.00 at Chardan Capital

Forte Biosciences (NASDAQ:FBRX) had its price target raised by Chardan Capital from $3.00 to $64.00 in a research report sent to investors on Friday,Benzinga reports. Chardan Capital currently has a buy rating on the stock.

Forte Biosciences Stock Performance

Shares of FBRX stock traded up $0.26 on Friday, reaching $5.84. The stock had a trading volume of 11,205 shares, compared to its average volume of 4,489. The stock has a market cap of $8.53 million, a P/E ratio of -0.31 and a beta of 0.04. Forte Biosciences has a 1 year low of $4.11 and a 1 year high of $21.25. The company has a 50 day simple moving average of $5.49 and a 200 day simple moving average of $2.29.

Forte Biosciences (NASDAQ:FBRX) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.11). On average, equities research analysts anticipate that Forte Biosciences will post -22.5 earnings per share for the current fiscal year.

About Forte Biosciences

Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.